Development of inhibitors to coagulation factor VIII or IX is still the most challenging
complication in haemophilia care.'Bypassing agents' may be used to treat a bleed but the …

Background Emicizumab is a bispecific antibody that bridges factor IXa and factor X to
restore hemostasis in patients with hemophilia A (HA). Its efficacy and safety have been …

Hemophilia A (HA) and hemophilia B (HB) are rare congenital severe bleeding disorders,
that may be controlled by proper administration of adequate prophylaxis with factor VIII …

Introduction Patients with hemophilia (PWH) constantly suffer hemarthrosis, which leads to
deformity of the hip joint. Therefore, PWH who are going to receive total hip arthroplasty …

Bilateral synchronous total hip arthroplasty for end-stage a... : Medicine Bilateral synchronous
total hip arthroplasty for end-stage arthropathy in hemophilia A patients: A retrospective study …

Background Reliable monitoring of coagulation factor replacement therapy in patients with
severe haemophilia, especially those with inhibitors, is an unmet clinical need. While useful …

Background: Rigorous haemostatic control and careful rehabilitation are essential for
haemophilic patients undergoing total hip arthroplasty (THA). Aim: to examine the current …

Little is known about the challenging treatment of pediatric patients with hemophilia B and
inhibitors due to disease rarity. We describe three patients diagnosed in childhood and …

La hemofilia adquirida es un trastorno hemorrágico producido por anticuerpos del propio
organismo que actúan frente al factor VIII. Posee una incidencia estimada 1-1, 5 …